Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment by et al, et al.
Title
Cardiovascular disease, chronic kidney disease, and diabetes
mortality burden of cardiometabolic risk factors from 1980 to
2010: A comparative risk assessment
Author(s) Global Burden of Metabolic Risk Factors for Chronic DiseasesCollaboration,; Lam, TH; Xu, L; Schooling, CM; et al,
Citation The Lancet Diabetes & Endocrinology, 2014, v. 2 n. 8, p. 634-647
Issued Date 2014
URL http://hdl.handle.net/10722/240867
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
634 www.thelancet.com/diabetes-endocrinology   Vol 2   August 2014
Articles
Cardiovascular disease, chronic kidney disease, and diabetes 
mortality burden of cardiometabolic risk factors from 1980 
to 2010: a comparative risk assessment
The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration*
Summary
Background High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular 
diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated 
mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four 
cardiometabolic risk factors for all countries and regions from 1980 to 2010.
Methods We used data for exposure to risk factors by country, age group, and sex from pooled analyses of population-
based health surveys. We obtained relative risks for the eﬀ ects of risk factors on cause-speciﬁ c mortality from meta-
analyses of large prospective studies. We calculated the population attributable fractions for- each risk factor alone, 
and for the combination of all risk factors, accounting for multicausality and for mediation of the eﬀ ects of BMI by 
the other three risks. We calculated attributable deaths by multiplying the cause-speciﬁ c population attributable 
fractions by the number of disease-speciﬁ c deaths. We obtained cause-speciﬁ c mortality from the Global Burden of 
Diseases, Injuries, and Risk Factors 2010 Study. We propagated the uncertainties of all the inputs to the ﬁ nal estimates.
Findings In 2010, high blood pressure was the leading risk factor for deaths due to cardiovascular diseases, chronic 
kidney disease, and diabetes in every region, causing more than 40% of worldwide deaths from these diseases; high 
BMI and glucose were each responsible for about 15% of deaths, and high cholesterol for more than 10%. After 
accounting for multicausality, 63% (10·8 million deaths, 95% CI 10·1–11·5) of deaths from these diseases in 2010 
were attributable to the combined eﬀ ect of these four metabolic risk factors, compared with 67% (7·1 million deaths, 
6·6–7·6) in 1980. The mortality burden of high BMI and glucose nearly doubled from 1980 to 2010. At the country 
level, age-standardised death rates from these diseases attributable to the combined eﬀ ects of these four risk factors 
surpassed 925 deaths per 100 000 for men in Belarus, Kazakhstan, and Mongolia, but were less than 130 deaths 
per 100 000 for women and less than 200 for men in some high-income countries including Australia, Canada, France, 
Japan, the Netherlands, Singapore, South Korea, and Spain.
Interpretation The salient features of the cardiometabolic disease and risk factor epidemic at the beginning of 
the 21st century are high blood pressure and an increasing eﬀ ect of obesity and diabetes. The mortality burden 
of cardiometabolic risk factors has shifted from high-income to low-income and middle-income countries. Lowering 
cardiometabolic risks through dietary, behavioural, and pharmacological interventions should be a part of the global 
response to non-communicable diseases.
Funding UK Medical Research Council, US National Institutes of Health.
Introduction
Cardiovascular diseases, chronic kidney disease, and 
diabetes are among leading global and regional causes 
of death.1,2 Between 1990 and 2010, the total number of 
deaths caused by cardiovascular diseases increased by 
more than 25% and those of chronic kidney disease and 
diabetes nearly doubled.1 Adiposity and high blood 
pressure, cholesterol, and glucose are important 
modiﬁ able risk factors for cardiovascular diseases and 
(except for cholesterol) for chronic kidney disease.3–6 
Adiposity is also the most important modiﬁ able risk 
factor for diabetes.3,4,7 Over the past few decades, these 
risk factors have had divergent trajectories in many 
countries. While BMI and blood glucose have increased 
in most countries and worldwide,8,9 mean blood pressure 
has fallen in high-income and some middle-income 
regions; it has remained unchanged or even increased 
in some low-income and middle-income countries.10 
Mean serum total cholesterol has also fallen in many 
parts of Europe, north America, and Australasia while 
increasing in east and southeast Asia, especially China, 
Japan, and Thailand.11
Previous comparative risk assessments12,13 have 
reported global and some regional estimates of the 
eﬀ ects of cardiometabolic risk factors on mortality. 
However, these studies did not analyse the combined 
eﬀ ects of the risk factors, partly because reliable estimates 
of how much of the eﬀ ect of adiposity on cardiovascular 
diseases is mediated through blood pressure, blood 
glucose, and serum cholesterol concentration were 
unavailable at the time.14 The only analysis15 of the 
combined eﬀ ects of these risks divided the world into 
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three large regions and did not include high blood 
glucose as a risk factor. Additionally, previous studies 
used broad disease categories—for example, all 
cardiovascular diseases, rather than speciﬁ c diseases of 
public health or clinical relevance such as stroke 
subtypes. Finally, very little is known about how much 
the eﬀ ects of these risk factors on mortality have changed 
over time, even though both the prevalence of risk factors 
and cardiometabolic death rates have changed 
enormously, sometimes in opposite directions. We 
estimated cause-speciﬁ c mortality from cardiovascular 
diseases, chronic kidney disease, and diabetes attributable 
to the eﬀ ects of high BMI, blood pressure, blood glucose, 
and serum cholesterol, individually as well as in 
combination, by country and region from 1980 to 2010.
Methods
Data sources 
We used measures of exposure to cardiometabolic risk 
factors for which the most comprehensive worldwide 
data were available—namely, BMI, fasting plasma 
glucose, systolic blood pressure, and serum total 
cholesterol. We derived population exposure to risk 
factors by country, year, sex, and age group from pooled 
analyses of population-representative health surveys as 
described in detail elsewhere.8–11 Brieﬂ y, we collated 
population-based data from published and unpublished 
national, subnational, and community surveys and 
studies done between 1980 and 2010. We used 960 data 
sources across countries and years for BMI, 786 for 
systolic blood pressure, 370 for fasting plasma glucose, 
and 321 for total cholesterol.8–11 About 50% of data for 
BMI in low-income and middle-income countries were 
from the 2000s and another 34% from the 1990s, whereas 
for high-income regions, data were evenly distributed 
over time.9 The data for systolic blood pressure were 
distributed almost equally among the three decades of 
analysis, but more than 60% of national sources were 
from the 2000s.10 About 40% of all data for total cholesterol 
and two-thirds of all national data were from the 2000s.11 
Half of the data for fasting plasma glucose and 68% of 
the national data, were from the 2000s, and another 35% 
from the 1990s.8
We used a Bayesian hierarchical model to estimate the 
levels of risk factors by sex and age group for all 
countries and years, sharing and borrowing information 
across space, time, and age as well as through covariates 
that helped predict risk factor levels.8–11,16 The 
uncertainties of the estimates incorporated the sampling 
error of the data, as well as uncertainty resulting from 
some data sources not being nationally representative 
and from missing data. We estimated the standard 
deviations (SDs) of distributions of risk factors for each 
country-year-age-sex unit using the population mean 
and the coeﬃ  cients of a regression that related SD to 
mean. We corrected SDs for systolic blood pressure, 
total cholesterol, and fasting plasma glucose for the 
error associated with one-oﬀ  measurements by use of 
coeﬃ  cients from prospective studies with multiple 
measurements.17–19
We quantiﬁ ed the eﬀ ects of each risk factor on speciﬁ c 
cardiovascular disease outcomes (ischaemic heart 
disease, ischaemic and haemorrhagic strokes, hyper-
tensive heart disease, and other cardiovascular diseases), 
diabetes, and chronic kidney disease when there was 
evidence of a convincing or probable causal association.3 
For each risk factor–disease pair, we used the age-speciﬁ c 
relative risk (RR) from meta-analyses of prospective 
studies that had adjusted for major confounders and to 
the extent possible for regression dilution bias. The RRs 
for eﬀ ects on cardiovascular diseases and diabetes are 
reported elsewhere, as is the RR for the eﬀ ect of high 
BMI on chronic kidney disease.3,4,20 The RR for the eﬀ ect 
of high blood pressure on chronic kidney disease from 
pooled analysis of prospective cohorts was 1·28 (1·18–
1·39) per 10 mm Hg higher systolic blood pressure 
(unpublished data).
We estimated what proportion of the eﬀ ects of BMI on 
ischaemic heart disease and stroke was mediated through 
the other three risk factors from a pooled analysis of 
97 prospective cohort studies.14 This pooled analysis 
showed that 46% (95% CI 42–50) of the excess RR of BMI 
on ischaemic heart disease and 76% (65–91) on stroke 
were mediated through the other three risk factors.14 We 
assumed that the eﬀ ect of high BMI on hypertensive 
heart disease is fully mediated through blood pressure, 
on diabetes through fasting plasma glucose con-
centration, and on chronic kidney disease through the 
combination of systolic blood pressure and fasting 
plasma glucose concentration.
We used estimates of the number of deaths by 
underlying cause from the Global Burden of Diseases, 
Injuries, and Risk Factors 2010 Study, with data sources 
and methods described in detail elsewhere.1 Brieﬂ y, total 
and cause-speciﬁ c death rates were estimated from data 
from vital registration, sample death registration 
systems, verbal autopsy studies, censuses, household 
surveys, and mortuaries. Deaths assigned to impossible 
and improbable causes of death were re-distributed, and 
statistical models were used to estimate cause-speciﬁ c 
death rates by country, year, sex, and age group, with 
speciﬁ c models selected on the basis of data quality and 
performance of the model. Like risk factors, there were 
substantially more data for causes of death in recent 
years than for the 1980s.1
Statistical analysis
We calculated population attributable fractions, which 
quantify the proportion of deaths from each cause that 
would have been prevented if the risk factor distribution 
had been set to an optimal level in the population. We 
calculated population attributable fractions as described 
elsewhere,12,13,21 using data for exposure distributions and 
RRs for each risk factor–disease pair. The number of 
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deaths attributable to each risk factor is a product of the 
population attributable fraction and the cause-speciﬁ c 
deaths for each country-year-sex-age group unit. The 
optimal levels were based on the levels corresponding to 
lowest all-cause mortality from reliable epidemiological 
studies.3 To account for the uncertainty of these optimal 
distributions, we allowed them to take a range with 
means of 110–115 mm Hg (SDs 4–6) for systolic blood 
pressure; 3·8–4·0 mmol/L (0·50–0·65) for total 
cholesterol; 21–23 kg/m² (1·1–1·8) for BMI; and 
4·9–5·3 mmol/L (0·4–0·6) for fasting plasma glucose.3 
The beneﬁ ts of lowering BMI for haemorrhagic stroke 
were estimated only for values above 25 kg/m², because 
there seems to be no reduction in risk below this level.4
The number of cause-speciﬁ c deaths attributable to 
multiple risk factors is often less than the sum of those 
attributable to individual risk factors because some 
deaths are the result of more than one risk factor 
(multicausality), and because some of the eﬀ ects of BMI 
are mediated through the other three risk factors.14 In the 
absence of mediation, eﬀ ect modiﬁ cation, and risk factor 
correlation, the combined eﬀ ects of multiple risk factors 
can be calculated on the basis of their individual 
population attributable fractions using a simple 
relationship that incorporates multicausality as described 
elsewhere.15 To use this relationship in the presence of 
mediation, we calculated the direct eﬀ ect of BMI on the 
relevant disease outcomes (ie, the part not mediated by 
the other three risks). We then tested the sensitivity of 
our ﬁ ndings to the correlation between risk factors. We 
used both an empirical correlation matrix from the 
continuous US National Health and Nutrition 
Examination Survey 1999–2010 (with pairwise correlation 
coeﬃ  cients of between 0·11 and 0·31) and another 
correlation matrix with substantially larger pairwise 
correlation coeﬃ  cients of 0·8.
Our analysis covered 187 countries for which estimates 
of deaths by cause were available. We obtained regional 
and worldwide results by population weighting country 
estimates. We combined age-speciﬁ c death rates into 
broader ages (25–69 and ≥70 years). We calculated age-
standardised death rates with use of the WHO standard 
population.22
We propagated the uncertainties of all inputs (risk 
factor exposure distributions, RRs, proportion of excess 
risk from BMI mediated through the other three risks, 
and cause-speciﬁ c deaths) to the ﬁ nal estimates with a 
simulation approach. Speciﬁ cally, we used 1000 draws 
from the uncertainty distributions of each input, and 
repeated the calculations with these draws. The resulting 
1000 population attributable fractions and attributable 
deaths characterised the distributions of the outputs. We 
report the median of these draws as the central estimates 
and their 2·5th and 97·5th percentiles as the 95% 
credible or conﬁ dence interval. Draws for diﬀ erent 
analysis units might be correlated (eg, in two age groups 
or countries for risk factor exposures and cause-speciﬁ c 
deaths because they came from a common statistical 
model). We took these correlations into account by taking 
correlated draws across countries, age groups, and years. 
We did all statistical analyses with Stata (version 12.0) 
and R (version 3.02).
Role of the funding source 
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
YL, GMS, and EC together had full access to all data used 
in this study. ME was responsible for submitting the 
article for publication.
Results
Between 1980 and 2008, age-standardised global mean 
BMI increased by 0·4 kg/m² per decade (95% CI 
0·2 to 0·6) for men and 0·5 kg/m² per decade (0·3 to 0·7) 
for women. Mean BMI for men increased in every region 
except central Africa and south Asia, with the largest 
increase in Oceania. The largest rise in women’s BMI 
also occurred in Oceania, followed by southern and 
central Latin America. BMI did not change for women in 
central and eastern Europe and central Asia. Between 
1980 and 2008, worldwide systolic blood pressure fell by 
0·8 mm Hg per decade (95% CI –0·4 to 2·2) for men 
and 1·0 mm Hg per decade (–0·3 to 2·3) for women. 
Systolic blood pressure decreased most in high-income 
countries for men and women. Systolic blood pressure 
rose in Oceania, east Africa, south Asia, and southeast 
Asia for both sexes, and in west Africa for women. 
Globally, mean serum total cholesterol concentration 
changed little between 1980 and 2008, falling by less than 
0·1 mmol/L per decade for men and women. Total serum 
cholesterol fell in Europe, Australasia, and north America 
but increased in east and southeast Asia and Paciﬁ c. We 
found little evidence of a change in Latin America and 
the Caribbean, the Middle East and north Africa, south 
Asia, and sub-Saharan Africa. Global age-standardised 
mean fasting plasma glucose increased by 0·07 mmol/L 
per decade (95% CI –0·02 to 0·15) for men  and 
0·09 mmol/L per decade (0·00 to 0·17) for women, with 
increases or, at best, no change in every region. The 
largest increase in fasting plasma glucose occurred in 
Oceania. Risk factor trends by country and region are 
described in detail elsewhere.8–11
In 2010, cardiovascular diseases, chronic kidney 
disease, and diabetes were together responsible for 
17·6 million (33%) of 52·8 million deaths worldwide.1 
The number of deaths from these causes attributable to 
individual cardiometabolic risks ranged between 
2·0 (1·5–2·5) million for high serum cholesterol 
and 7 ·7 (6·9–8·4) million for high blood pressure. After 
accounting for multicausality, the four risk factors 
together were responsible for 63% (10·8 million, 95% CI 
10·1–11·5) of deaths caused by cardiovascular diseases, 
chronic kidney disease, and diabetes, accounting for one 
in every ﬁ ve deaths worldwide. These deaths were divided 
For the US National Health and 
Nutrition Examination Survey 
1999–2010 see http://www.cdc.
gov/nchs/nhanes.htm
Articles
www.thelancet.com/diabetes-endocrinology   Vol 2   August 2014 637
almost equally between men (5·5 million, 5·0–5·9) and 
women (5·3 million, 4·7–5·8; ﬁ gure 1A). The combined 
mortality burden of the four risk factors was 7·1 million 
(67%) of 10·6 million deaths worldwide (95% CI 6·6–7·6) 
in 1980, increasing steadily throughout the three decades 
of analysis, driven by population growth and aging. 
Although high blood pressure was the leading risk factor 
throughout the analysis period, high cholesterol was 
responsible for the second most deaths until 1990. High 
BMI and blood glucose had smaller eﬀ ects in 1980, each 
responsible for around 1·2 million deaths; this number 
had doubled by 2010.
After accounting for population size and aging, age-
standardised deaths attributable to the four risk factors 
fell steadily worldwide, and in high-income regions, Latin 
America and the Caribbean, and the Middle East and 
north Africa, between 1980 and 2010 (ﬁ gure 2). In high-
income regions, this fall was caused by a combination of 
decreasing population attributable fractions (themselves 
driven by lower systolic blood pressure and total serum 
cholesterol) and lower cardiovascular death rates; 
elsewhere, falling mortality was the main driver.23,24 Age-
standardised death rates attributable to risk factors 
increased in south Asia because both risk factor levels 
and total death rates increased; they did not change in 
sub-Saharan Africa and decreased only slightly in central 
and eastern Europe and central Asia. There was, however, 
a steeper decline in central and eastern Europe and 
central Asia after 2000.
In 1980, the number of deaths attributable to these 
four risk factors in high-income regions was larger 
than that in any of the low-income and middle-income 
regions; high-income regions accounted for 35% 
(2·5 milion of 7·1 million) of deaths attributable to the 
combined eﬀ ects of high BMI, blood pressure, blood 
glucose, and serum cholesterol, whereas low-income 
and middle-income regions accounted for the 
remaining 65% (ﬁ gure 1A). By 2010, low-income and 
middle-income regions accounted for 82% (8·8 million 
of 10·8 million) of attributable deaths, and the two 
regions with the largest number of attributable deaths 
were east and southeast Asia and Paciﬁ c (3 million 
deaths or 28% of all deaths attributable to these risks), 
followed by central and eastern Europe and central Asia 
(2 million deaths). In fact, from 1980 to 2010, the 
number of deaths attributable to high blood pressure 
and cholesterol fell in high-income regions, despite 
population increase and aging, and those attributable to 
high BMI and blood glucose increased only slightly. In 
low-income and middle-income regions, the number of 
deaths attributable to these four risk factors increased 
or remained stable over time. In 2010, east and 
southeast Asia and Paciﬁ c also had the largest mortality 
burden of high blood glucose and blood pressure—30% 
of deaths attributable to high blood pressure worldwide 
occurred in this region. However, mortality burden of 
high BMI and serum cholesterol were still largest in 
high-income regions and in central and eastern Europe 
and central Asia in 2010.
40% (4·3 million of 10·8 million) of deaths attributable 
to these four risk factors in 2010 occurred in people aged 
younger than 70 years and thus caused greater loss of life 
years than deaths of older people (ﬁ gure 1B). Deaths 
before age 70 years made up a smaller proportion of the 
mortality burden of the four risk factors in high-income 
regions (21% of all attributable deaths) and in central and 
eastern Europe and central Asia (33%) than in other 
regions. The share of attributable deaths before age 70 
years was greatest in south Asia (55%) and sub-Saharan 
Africa (58%). Deaths attributable to the four risk factors 
shifted to older ages over time in high-income regions, 
where 31% of deaths attributable to the risk factors 
occurred in people younger than age 70 years in 1980 
(compared with 21% in 2010). A similar shift occurred in 
Latin America and the Caribbean but not in other regions.
Figure 1: Deaths from cardiovascular diseases, diabetes, and chronic kidney disease attributable to the 
individual and combined eﬀ ects of high BMI, blood pressure, serum cholesterol, and blood glucose by region 
and sex (A) and age group (B), 1980–2010
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In every region and through the whole analysis period, 
high blood pressure was the leading risk factor for 
mortality, but the relative importance of other risks varied 
by region and over time (appendix). In 1980, high blood 
pressure was followed by either high cholesterol or high 
glucose for every region and sex, except for women in the 
Middle East and north Africa, for whom high BMI was the 
second leading risk factor. By 2010, the relative importance 
of high cholesterol fell, and its mortality burden was in the 
third or fourth greatest for every region and sex; blood 
pressure was followed by either high BMI or high blood 
glucose, a result of the worldwide rise in excess weight 
and hyperglycaemia. The increasing importance of high 
BMI as a risk factor accelerated after 1990.
Overall, 44% (4·7 million of 10·8 million) of deaths 
attributable to the combined eﬀ ects of these risk factors 
in 2010 were from ischaemic heart disease, followed by 
30% from stroke, and 11% from diabetes (ﬁ gure 3). 
Ischaemic heart disease was the single most dominant 
cause of death attributable to high cholesterol (92% [1·80 
of 1·95] of all deaths attributable to this risk factor), 
whereas about the same number of deaths caused by 
ischaemic heart disease and stroke were attributable to 
high blood pressure. Deaths directly assigned to diabetes 
accounted for only 46% (1·24 million of 2·66 million) of 
deaths caused by high blood glucose, with the remainder 
having ischaemic heart disease, ischaemic stroke, or 
chronic kidney as the underlying clinical causes of death.
After accounting for multicausality, 63% (CI 59–67) of 
all deaths caused by cardiovascular diseases, chronic 
kidney disease, and diabetes among men and 62% (56–67) 
among women were attributable to the four risk factors 
together in 2010 (table). In 1980, the population 
attributable fractions were 67% (62–72) for men and 
66% (61–72) for women (detailed results not shown). 
High blood pressure alone was responsible for more 
than 40% of deaths caused by these three diseases, high 
BMI and glucose concentration were each responsible 
for about 15% of deaths, and cholesterol for more than 
10%. Although high cholesterol was responsible for 
fewer deaths from the combination of cardiovascular 
diseases, chronic kidney disease, and diabetes in 2010 
compared to the other three risk factors, it caused the 
second most deaths caused by ischaemic heart disease, 
about twice that of high glucose. High BMI and glucose 
were responsible for fewer deaths caused by ischaemic 
heart disease than was high cholesterol, but were also 
associated with deaths from haemorrhagic stroke, 
diabetes, and chronic kidney disease, none of which are 
aﬀ ected by high cholesterol. The combined population 
attributable fraction of the four risk factors together was 
about three quarters for hypertensive heart disease, 
about two thirds for ischaemic heart disease, and just 
more than a half for stroke and chronic kidney disease. 
The population attributable fraction for the eﬀ ects of all 
four risk factors combined increased by only 1 percentage 
point when we introduced a pairwise correlation between 
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Figure 2: Age-standardised death rates from cardiovascular diseases, diabetes, and chronic kidney disease 
attributable to the combined eﬀ ects of high BMI, blood pressure, serum cholesterol, and blood glucose by 
region for men (A) and women (B)
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Figure 3: Deaths attributable to the individual and combined eﬀ ects of high BMI, blood pressure, serum 
cholesterol, and blood glucose in 2010, by disease
CVD=cardiovascular disease. *For total stroke (RRs were for association between blood glucose and total stroke). 
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risk factors in two diﬀ erent sensitivity analyses (with 
empirical and low vs high correlation; data not shown).
At the country level (ﬁ gure 4), the proportion of deaths 
caused by cardiovascular diseases, chronic kidney 
disease, and diabetes that were attributable to the 
combined eﬀ ect of the four risk factors was lowest in 
Japan (<50%), followed by some other Asian countries 
(eg, Cambodia and South Korea), some western European 
countries, Canada, and Peru; it was highest in the Paciﬁ c 
islands and in some countries in the Middle East, such as 
Bahrain and Qatar, reaching 80% or more in Marshall 
Islands, Fiji, and Kiribati. The population attributable 
fraction for risk factors tended to be low or high for both 
men and women in the same country (correlation 
coeﬃ  cient between population attributable fractions for 
the two sexes was 0·81).
The geographical patterns of population attributable 
fractions for individual risk factors diﬀ ered from their 
combined eﬀ ect. High blood pressure was responsible 
for more than 55% of deaths caused by cardiovascular 
diseases, chronic kidney disease, and diabetes in central 
Asia, eastern Europe, and sub-Saharan Africa. By 
contrast, it was responsible for a third or less of such 
deaths in some high-income countries—including 
Canada, Switzerland, South Korea, USA, and Taiwan—
in Mexico, and in Papua New Guinea and a few other 
Paciﬁ c islands. Some of the countries with relatively 
low population attributable fraction for high blood 
pressure—including Paciﬁ c islands and Mexico—were 
disproportionately aﬀ ected by high BMI, as were some 
Middle Eastern countries and South Africa, with 
population attributable fractions surpassing a third. 
High BMI was responsible for 5% or less of deaths 
from cardiovascular diseases, chronic kidney disease, 
and diabetes in some south and southeast Asian 
countries (eg, Vietnam, Bangladesh, Nepal, Cambodia, 
and India), Japan, and a few African countries, such as 
Ethiopia, DR Congo, Eritrea, and Burkina Faso. The 
largest population attributable fractions for high blood 
glucose occurred in the Paciﬁ c islands, Mexico, a few 
Caribbean countries (eg, Trinidad and Tobago and 
Barbados), and some Middle Eastern countries (eg, 
Bahrain, Qatar, and Jordan). For example, in Samoa, 
Kiribati, and Marshall Islands, one half or more of 
deaths from cardiovascular diseases, chronic kidney 
disease, and diabetes were attributable to high blood 
glucose alone. Finally, the proportion of deaths 
attributable to high serum cholesterol ranged from less 
than 5% in much of sub-Saharan Africa, Vietnam, and 
Bangladesh to 20% or more in central and northern 
Number of deaths 
(95% CI; thousands)
PAF of risk factor (95% CI)
High blood 
pressure
High BMI High blood 
glucose
High serum 
cholesterol
Four risk factors 
combined
Men
All CVDs, diabetes, and CKD 8716 (8291–9201) 46% (42–51) 13% (12–15) 15% (13–18) 10% (8–13) 63% (59–67)
Hypertensive heart disease 387 (325–467) 76% (71–80) 24% (17–30) 0% 0% 76% (71–80)
Ischaemic heart disease 3705 (3341–3951) 48% (39–56) 16% (14–18) 12% (9–17) 23% (17–28) 67% (60–73)
Total stroke 2816 (2516–3226) 53% (46–59) 8% (7–10) 8% (6–11) 2% (1–6) 58% (52–65)
Haemorrhagic and other non-
ischaemic stroke
1585 (1263–1952) 57% (49–66) 7% (5–9) ·· 0% 61% (53–70)
Ischaemic stroke 1221 (1114–1593) 48% (40–55) 10% (8–12) ·· 5% (3–13) 54% (46–63)
Other CVDs 891 (822–964) 37% (33–40) 0% 0% 0% 37% (33–40)
Diabetes 569 (409–603) 0% 27% (11–43) 100% 0% 100%
Chronic kidney disease 357 (298–393) 45% (39–50) 24% (19–29) 23% (19–28) 0% 57% (52–62)
Women
All CVDs, diabetes, and CKD 8568 (8142–9005) 43% (35–49) 15% (12–17) 15% (13–18) 12% (8–17) 62% (56–67)
Hypertensive heart disease 469 (328–668) 75% (70–80) 28% (19–38) 0% 0% 75% (70–80)
Ischaemic heart disease 3263 (3063–3455) 45% (28–57) 17% (13–21) 11% (8–15) 29% (19–39) 69% (57–76)
Total stroke 2995 (2708–3246) 47% (38–55) 10% (8–12) 7% (5–10) 2% (1–12) 52% (44–62)
Haemorrhagic and other non-
ischaemic stroke
1439 (1205–1589) 52% (41–64) 10% (8–12) ·· 0% 56% (46–68)
Ischaemic stroke 1559 (1476–1719) 42% (29–52) 9% (7–13) ·· 4% (2–22) 49% (35–62)
Other CVDs 860 (807–905) 33% (27–37) 0% 0% 0% 33% (27–37)
Diabetes 667 (513–696) 0% 33% (14–51) 100% 0% 100%
Chronic kidney disease 345 (236–392) 46% (39–52) 29% (24–35) 23% (19–28) 0% 58% (53–63)
CVD=cardiovascular disease. CKD=chronic kidney disease. PAF=population attributable fraction. 
Table: Proportion of deaths attributable to the individual and combined eﬀ ects of high BMI, blood pressure, blood glucose, and serum total cholesterol 
in 2010
See Online for appendix
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Europe (Iceland, Finland, Belarus, Russia, Denmark, 
Lithuania, Russia, Estonia, and Germany) and wealthier 
Middle Eastern countries such as Kuwait and United 
Arab Emirates.
In 2010, age-standardised death rates attributable to 
these four risk factors were highest in countries in 
central Asia and eastern Europe (ﬁ gure 5), where 
population attributable fractions were large (because of 
high exposure) and mortality from cardiovascular 
diseases was high. For example, these four risk factors 
together were responsible for more than 925 deaths 
from cardiovascular diseases, chronic kidney disease, 
and diabetes per 100 000 men in Belarus, Mongolia, and 
Kazakhstan. The attributable death rates were lowest in 
high-income countries—Japan, Singapore, South Korea, 
France, Spain, the Netherlands, Australia, and Canada 
all had fewer than 130 deaths per 100 000 women and 
fewer than 200 deaths per 100 000 men. These countries 
had low adult mortality and low population attributable 
fractions because some metabolic factors are low 
compared with in other countries. Attributable death 
rates were also low in Senegal, Peru, Niger, and The 
Gambia, where death rates from non-communicable 
diseases were low because these countries are still in 
the early phases of the demographic and epidemiological 
transition. From 1980 to 2010, age-standardised death 
rates attributable to the combined eﬀ ects of these risk 
factors decreased in more than 120 countries, especially 
Figure 4: Proportion of deaths from cardiovascular diseases, diabetes, and chronic kidney disease attributable to individual and combined eﬀ ects of high BMI, 
blood pressure, blood glucose, and serum cholesterol in 2010
Note that the scales diﬀ er by panel.
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in high-income countries (data not shown). Although 
some of this decrease was caused by falling population 
attributable fractions (eg, because of declining trends 
for systolic blood pressure), the main driver was a 
decrease in overall cardiovascular disease mortality.
62% of all deaths attributable to the combined eﬀ ects 
of these four risk factors in 2010 occurred in ten 
countries, led by China, India, Russia, and USA 
(ﬁ gure 6), because they had large populations or high 
age-standardised death rates, or both. These four 
Figure 5: Age-standardised death rates from cardiovascular diseases, diabetes, and chronic kidney disease attributable to combined eﬀ ects of high BMI, blood 
pressure, blood glucose, and serum cholesterol by sex in 2010
Results are not shown for women in Afghanistan because despite relatively low population attributable fractions (ﬁ gure 4), they had the highest worldwide death 
rates attributable to these risk factors. This occurred because of very high cardiovascular death rates in the Global Burden of Diseases, Injuries, and Risk Factors 2010 
Study. The appendix shows results for women in Afghanistan.
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countries also accounted for the most deaths attributable 
to each individual risk factor, with the exception of the 
mortality burden of high BMI, for which India had the 
eighth highest burden. Over time, middle-income 
countries such as Mexico, Turkey, Egypt, and Indonesia 
have replaced high-income European countries such as 
the UK and France as places where a large number of 
deaths are attributable to these risk factors (ﬁ gure 6). 
1980
1 Russia 14·8 (12·6–17·0)
2 USA 12·8 (11·0–14·6)
3 Germany 7·7 (6·7–8·8)
4 Ukraine 5·0 (2·5–7·4)
5 China 4·6 (2·7–7·0)
6 Italy 4·4 (3·8–5·1)
7  3·6 (2·9–4·3)
8 Poland 3·1 (2·6–3·6)
9 France 2·5 (1·8–3·2)
10 Brazil 2·3 (1·4–3·3)
14 Turkey 1·5 (1·1–2·0)
17 Egypt 1·3 (0·8–1·8)
18 India 1·3 (0·2–3·7)
19 Mexico 1·2 (0·7–1·7)
1 Russia 12·0 (10·6–13·7)
2 China 10·5 (8·4–12·7)
3 USA 10·3 (9·4–11·6)
4 Brazil 4·4 (3·9–5·1)
5 Ukraine 3·5 (2·1–5·1)
6 Mexico 3·4 (2·0–5·0)
7 Germany 3·3 (2·9–4·0)
8 India 3·3 (2·9–3·9)
9 Egypt 3·0 (2·6–3·5)
10 Turkey 2·1 (1·9–2·4)
11 Italy 1·8 (1·6–2·3)
12 Poland 1·8 (1·6–2·1)
14 UK 1·6 (1·4–1·9)
20 France 1·2 (0·9–1·5)
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
High BMI
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
2010 1980
1 China 16·2 (10·9–21·9)
2 India 9·4 (5·7–13·3)
3 USA 8·7 (5·6–11·9)
4 Russia 6·8 (1·8–12·1)
5 Germany 5·7 (3·3–8·0)
6 Indonesia 3·4 (2·5–4·4)
7 Italy 3·0 (2·1–4·0)
8 UK 2·9 (1·4–4·5)
9 Ukraine 2·8 (0·5–5·3)
10 Mexico 1·9 (1·5–2·4)
11 Brazil 1·9 (1·1–3·2)
19 Pakistan 0·9 (0·5–1·4)
1 India 17·2 (13·7–20·5)
2 China 16·2 (12·6–19·8)
3 USA 7·6 (6·3–9·0)
4 Russia 5·1 (1·3–9·3)
5 Indonesia 4·1 (3·3–5·1)
6 Brazil 3·3 (2·4–4·3)
7 Mexico 3·3 (2·7–3·9)
8 Germany 2·3 (1·7–3·0)
9 Pakistan 2·3 (1·7–2·9)
10 Ukraine 1·9 (0·4–3·7)
11 Italy 1·6 (1·2–2·0)
17 UK 0·9 (0·6–1·3)
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
High blood glucose 
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
2010
1980
1 USA 16·1 (13·6–18·3)
2 Russia 13·5 (11·1–16·0)
3 Germany 7·4 (6·1–8·6)
4 UK
UK
5·8 (4·8–6·7)
5 India 5·4 (1·7–8·8)
6 Ukraine 5·3 (3·4–6·8)
7 China 4·1 (1·2–7·1)
8 Italy 3·2 (2·7–3·7)
9 France 2·6 (2·1–3·1)
10 Brazil 2·1 (1·2–2·8)
16 Japan 1·1 (0·8–1·4)
1 China 13·9 (9·1–18·0)
2 Russia 13·2 (7·4–17·5)
3 India 10·4 (4·5–15·6)
4 USA 8·1 (6·1–10·5)
5 Ukraine 4·6 (1·7–7·1)
6 Germany 4·0 (2·8–5·2)
7 Brazil 2·9 (1·7–4·1)
8 Italy 2·2 (1·7–2·8)
9 Japan 2·1 (1·6–2·8)
10 UK 2·0 (1·4–2·6)
14 France 1·4 (1·0–1·9)
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
High serum cholesterol 
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
2010 1980
1 China 17·3 (14·9–20·2)
2 USA 9·2 (8·1–10·3)
3 Russia 8·9 (7·9–9·8)
4 India 5·7 (3·6–7·5)
5 Germany 4·8 (4·4–5·4)
6 Ukraine 3·8 (3·3–4·3)
7 UK 3·3 (2·9–3·7)
8 Japan 2·9 (2·6–3·2)
9 Italy 2·9 (2·6–3·2)
10 Brazil 2·7 (2·3–3·0)
13 Indonesia 2·0 (1·4–2·4)
1 China 21·6 (19·2–24·0)
2 India 11·9 (9·4–14·1)
3 Russia 8·3 (7·3–9·4)
4 USA 4·6 (3·7–5·7)
5 Indonesia 4·1 (3·4–4·7)
6 Ukraine 3·4 (2·8–3·9)
7 Brazil 3·0 (2·6–3·4)
8 Japan 2·1 (1·8–2·5)
9 Germany 2·0 (1·6–2·4)
10 Italy 1·5 (1·3–1·8)
15 UK 1·1 (0·9–1·3)
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
High blood pressure
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
2010
1980
1 China 15·6 (13·7–18·0)
2 USA 10·2 (9·2–10·9)
3 Russia 8·8 (7·9–9·4)
4 India 6·6 (4·9–7·9)
5 Germany 5·1 (4·8–5·5)
6 Ukraine 3·7 (3·3–4·0)
7 UK 3·4 (3·1–3·7)
8 Italy 2·9 (2·7–3·1)
9 Japan 2·6 (2·3–2·8)
10 Brazil 2·5 (2·3–2·7)
12 Indonesia 2·1 (1·7–2·4)
1 China 19·4 (17·7–21·2)
2 India 12·8 (11·1–14·5)
3 Russia 7·8 (7·0–8·7)
4 USA 5·9 (5·4–6·6)
5 Indonesia 4·0 (3·5–4·5)
6 Ukraine 3·1 (2·6–3·4)
7 Brazil 3·0 (2·8–3·3)
8 Germany 2·3 (2·1–2·6)
9 Japan 2·0 (1·7–2·3)
10 Italy 1·6 (1·5–1·8)
15 UK 1·2 (1·1–1·4)
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
Combined eﬀect
Contribution to 
global attributable 
deaths (%, 95% CI)
Rank Country
2010
Latin America and Caribbean
Middle East and north Africa
High-income regions
Central and eastern Europe and central Asia
East and southeast Asia and Paciﬁc
South Asia
Figure 6: Ten countries with most deaths from cardiovascular diseases, diabetes, and chronic kidney disease attributable to high BMI, blood pressure, serum cholesterol, and blood glucose in 
1980 and 2010
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Other high-income countries such as Italy and Germany 
had lower ranks in 2010 in terms of number of deaths 
attributable to these risk factors, with increasing 
importance of middle-income countries such as Brazil 
and Ukraine.
Discussion
More than 60% of worldwide deaths from cardiovascular 
diseases, chronic kidney disease, and diabetes in 2010 
were attributable to four preventable cardiometabolic risk 
factors, with high blood pressure having the largest eﬀ ect. 
Over time, high blood pressure has maintained its role as 
the leading risk factor while the mortality burdens of high 
BMI and glucose increased faster than that of high 
cholesterol, such that these two risks are now responsible 
for more deaths than high cholesterol. High serum 
cholesterol nonetheless remains the second leading risk 
factor for deaths from ischaemic heart disease.
At present, the mortality burden of most of these risk 
factors is largest in east and southeast Asia and Paciﬁ c and 
in central and eastern Europe and central Asia, where 
many people die of cardiovascular diseases (predominantly 
stroke in east and southeast Asia and Paciﬁ c and ischaemic 
heart disease in central and eastern Europe and central 
Asia); central and eastern Europe and central Asia also 
have high levels of most cardiometabolic risk factors 
compared with other regions.8–11 The mortality burden has 
shifted from high-income to low-income and middle-
income countries because of a combination of 
demographic factors (faster population growth and aging) 
and divergent epidemiological trends (decreasing blood 
pressure and cholesterol, and cardiovascular death rates 
in high-income countries while risk factors increased or 
remained unchanged in low-income and middle-income 
regions). Deaths attributable to these risk factors occurred 
in younger people in low-income and middle-income 
regions than in high-income countries.
Our study is the most detailed analysis of the 
worldwide mortality burden of cardiometabolic risk 
factors, and the only study to analyse trends in mortality 
burden over a period of three decades and to report the 
individual and combined eﬀ ects of risk factors at the 
country level (panel). We used data for risk factor 
exposure, individual and joint associations of risk 
factors with disease-speciﬁ c mortality, and cause-
speciﬁ c deaths from comprehensive up-to-date pooling 
studies.1,3,8–11,14 We also quantiﬁ ed the uncertainties of 
our estimates.
Our study also has some limitations. Despite using 
much more data than previous analyses, risk factor 
exposures and deaths in some regions were aﬀ ected by 
data shortages and had large uncertainty. Second, we 
used RRs from observational studies, which could have 
been aﬀ ected by residual confounding. For high blood 
pressure and serum cholesterol, overwhelming evidence 
from randomised trials of antihypertensive and 
cholesterol-lowering drugs support the relative risks 
from observational studies.17,33,34 The causal eﬀ ects of high 
BMI are supported by follow-up of patients after bariatric 
surgery and randomised trials of lifestyle and diet 
interventions that have shown that weight loss helps to 
prevent diabetes.35 Results of some randomised trials 
showed that intensive glucose lowering did not 
signiﬁ cantly reduce cardiovascular disease mortality of 
patients with diabetes.36 The reasons for these ﬁ ndings 
might be that intensive glucose lowering was compared 
with usual care (rather than with placebo), participants 
were generally old and frail, patients had had diabetes for 
a long time at baseline, the high prevalence of existing 
atherosclerotic disease at trial entry, and low incidence of 
cardiovascular disease in the trial populations because of 
concurrent treatment with statins, aspirin, and 
antihypertensive drugs, which reduced the power of the 
trials to detect an eﬀ ect.36 Subsequently, several meta-
analyses37–39 of randomised trials of intensive versus 
moderate glucose lowering for patients with diabetes 
have shown that such treatment signiﬁ cantly reduces the 
risk of myocardial infarction and other major 
cardiovascular events. In particular, a meta-analysis of 
the four largest randomised trials concluded that highly 
intensive glucose lowering causes a modest but 
signiﬁ cant cardiovascular beneﬁ t in the short to medium 
term.38 For these reasons, and in view of the overwhelming 
evidence from observational studies of the graded 
increase in risk of cardiovascular disease caused by 
impaired glucose metabolism, we included ischaemic 
heart disease and stroke as outcomes of high blood 
glucose. Nevertheless, for both high BMI and blood 
glucose, residual confounding remains a concern. 
We used the same RRs for all countries. Although the 
results of large cohort pooling studies3,7,14 suggest that RRs 
(and mediation of the excess risk of BMI by other 
cardiometabolic risk factors) are similar for populations 
in western and Asian cohorts, further evidence about the 
size of RRs would be useful—for example, from Africa 
and Latin America. In addition to mediation, the 
combined population attributable fractions for multiple 
risk factors depend on correlation of exposures and on 
eﬀ ect size modiﬁ cation, for which we did not have data. 
In sensitivity analyses, our results were robust to 
correlations of risk factor exposures. We used serum total 
cholesterol to measure population exposure to high 
cholesterol because substantially more data were available 
for total cholesterol than for other measures such as LDL-
cholesterol or non-HDL-cholesterol and for apolipo-
proteins.11 Findings in countries with data for both 
total cholesterol and LDL-cholesterol (each with a 
corresponding RR) show that the estimated attributable 
deaths are comparable.21 Similarly, we used BMI as our 
measure of adiposity to take advantage of decades of 
worldwide data for height and weight. However, measures 
of abdominal obesity, such as waist circumference and 
waist-to-hip ratio, seem to have independent eﬀ ects on 
mortality even after accounting for BMI.40 
Articles
644 www.thelancet.com/diabetes-endocrinology   Vol 2   August 2014
Our analysis focused on eﬀ ects on only cardiovascular 
diseases, chronic kidney disease, and diabetes which are 
causally related. High BMI is also a risk factor for some 
types of cancer and responsible for an estimated 320 000 
cancer deaths worldwide in 2010.12 High glucose 
concentration is associated with increased risk of 
tuberculosis.41 Finally, the remaining deaths caused by 
cardiovascular diseases, chronic kidney disease, and 
diabetes—which ranged from 20% to more than 50% in 
diﬀ erent countries—might be a result of factors not 
considered in our analysis, independently or in interaction 
with genetic factors. For example, more than 10% of all 
deaths caused by cardiovascular diseases are attributable 
to smoking,42 which would make the combined eﬀ ects of 
cardiometabolic risk factors and smoking about 70% 
worldwide. Unhealthy diets, insuﬃ  cient physical activity, 
and harmful alcohol use are risk factors for cardiovascular 
diseases and diabetes, with their eﬀ ects partly or fully 
mediated through the cardiometabolic factors covered in 
the present work. Fetal and early childhood undernutrition 
increases the risk of cardiovascular diseases and diabetes; 
infections and environmental pollutants are also risk 
factors for chronic kidney disease.43 Inﬂ ammation, caused 
by infections and other environmental factors, is a risk 
factor for cardiovascular diseases, chronic kidney disease, 
and possibly diabetes.44,45 There is increasing evidence 
that stress, insuﬃ  cient sleep, and other psychosocial 
factors are independent risk factors for cardiovascular 
and other non-communicable diseases.
Our results have important implications for the 
prevention and control of non-communicable diseases 
throughout the world.32 Interventions to lower blood 
pressure, such as reducing dietary salt and better 
diagnosis and treatment, have successfully reduced blood 
pressure in high-income countries,46–48 which has in turn 
been an important determinant of the fall in deaths from 
cardiovascular diseases.49 Interventions to reduce blood 
pressure are urgently needed for low-income and middle-
income countries, where salt intake remains high and 
coverage of treatment with anti-hypertensive drugs is 
low.50–52 Salt from packaged and prepared foods is a 
relatively small component of total salt intake in these 
countries, therefore alternative locally accepted 
approaches to reduce salt intake are needed.53,54 Similarly, 
scaling up drug treatments requires a universal and high-
quality primary care system as well as national guidelines 
for identiﬁ cation of people who are in need of intervention, 
either based on the presence of a single risk factor or on 
their absolute risk of an adverse event.51,55 
High-income countries in Europe, north America, and 
Australasia have also reduced the prevalence of high serum 
cholesterol concentrations through a combination of 
replacing saturated fats with unsaturated fats and higher 
coverage of treatment.11,56–58 Although high cholesterol had 
the lowest mortality burden of these risk factors 
worldwide, it has increased in east and southeast Asian 
countries such as Japan, China, and Thailand, possibly as 
a result of increased intake of meat, animal fats, and 
dairy.11,59 The number of deaths from cardiovascular 
diseases attributable to high serum cholesterol increased 
by about 250% in the east and southeast Asia and Paciﬁ c 
regions between 1980 and 2010, more than those 
attributable to blood pressure and glucose but less than 
BMI. Dietary and health-care interventions for lowering 
serum cholesterol are needed in this region. Finally, access 
to and quality of health care is one of the most important 
determinants of variation in mortality caused by 
cardiovascular diseases, chronic kidney disease, and 
diabetes both across and within countries.
Unlike national successes for reducing blood pressure 
and cholesterol, most countries have had increases of 
BMI and blood glucose;8–11 a trend shown by the larger 
increase of their mortality burden than those of high 
blood pressure and cholesterol. Randomised studies of 
diet and lifestyle change have shown that moderate 
weight loss can be beneﬁ cial for up to 2 years,60–62 and 
reduces diabetes incidence.63 However, the long-term and 
community eﬀ ectiveness of such interventions is not 
clear.64 Simple advice and exercise alone have not been 
eﬃ  cacious, even in randomised trials.62 The rising 
burdens of high BMI and glucose, which can be only 
partly addressed through interventions to reduce blood 
Panel: Research in context
Systematic review
We searched PubMed with the terms “comparative risk 
assessment” AND (“cardiovascular disease” OR “chronic 
kidney disease” OR “diabetes”) for articles in English 
published before April 9, 2014. We also identiﬁ ed articles 
thorough the references for comparative risk assessment 
studies. We found some articles that had reported the 
mortality burden of individual or multiple cardiometabolic 
risk factors for one or more countries (including 
subnationally), for speciﬁ c diseases or all-cause mortality, for 
one or at most two points in time.12,13,15,21,25–31
Interpretation
Our study shows that more than 60% of deaths worldwide 
from cardiovascular diseases, chronic kidney disease, and 
diabetes are attributable to four cardiometabolic risk 
factors—high BMI, blood pressure, blood glucose, and serum 
cholesterol—which can be prevented through a combination 
of population-based and personal interventions. The largest 
mortality burden was caused by high blood pressure but 
mortality caused by high BMI and high blood glucose has 
increased more quickly since 1980 than those of the other 
two risks. Successful initiatives to reduce population blood 
pressure and cholesterol should be replicated on a wider scale, 
and eﬀ ective and scalable interventions need to be developed 
to curb or reverse the rising trends of BMI and 
hyperglycaemia.32 Periodic representative country data for 
cardiometabolic risk factors are needed to improve the 
estimates and monitor trends.
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pressure and cholesterol, shows the urgent need for 
developing and testing new approaches to prevention of 
obesity. These approaches would have to go beyond health 
promotion at the individual level, and use ﬁ scal and 
regulatory mechanisms to motivate changes in diet and 
lifestyle.46,65 Actions to reduce exposure to cardiometabolic 
risk factors (and smoking) will also contribute 
signiﬁ cantly towards achieving the global 25×25 target for 
non-communicable disease mortality.32
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